Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development

Set Alert for Research & Development

Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population

Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.

Business Strategies Clinical Trials

Cellino Raises $80m Series A To Transform Stem Cell Therapy Manufacturing

The Cambridge, MA start-up aims to ‘democratize’ therapies based on induced pluripotent stem cells by developing an automated manufacturing system.

Biologics Companies

Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?

The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.

Ophthalmic Biologics

Sanofi Pairs Up With Non-Profit Protas In Quest To Cut Clinical Trial Costs

The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.

Clinical Trials Cost Effectiveness

Pipeline Watch: Six Japanese Approvals Plus Eight Phase III Trial Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1

Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.

Clinical Trials Companies

Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data

Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.

Cancer ImmunoOncology

Big Names Backers Give Altos $3bn To Pursue Cell Rejuvenation Science

Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."

Regenerative Medicine Research & Development

Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic

The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.

Financing Deals

Hal Barron To Depart GSK To Head Up New Biotech

As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.

Companies Research & Development

China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle

Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.

China Gene Therapy
UsernamePublicRestriction

Register